Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.

Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7095-7100. doi: 10.1073/pnas.1704706114. Epub 2017 Jun 19.

PMID:
28630349
2.

Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.

Thorpe LM, Schrock AB, Erlich RL, Miller VA, Knost J, Le-Lindqwister N, Jujjavarapu S, Ali SM, Liu JJ.

Head Neck. 2017 Mar;39(3):E40-E44. doi: 10.1002/hed.24634. Epub 2016 Dec 22.

PMID:
28006087
3.

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ.

Cell Discov. 2016 Sep 20;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016.

4.

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Thorpe LM, Yuzugullu H, Zhao JJ.

Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860. Review.

5.

Apical constriction and invagination downstream of the canonical Wnt signaling pathway require Rho1 and Myosin II.

Zimmerman SG, Thorpe LM, Medrano VR, Mallozzi CA, McCartney BM.

Dev Biol. 2010 Apr 1;340(1):54-66. doi: 10.1016/j.ydbio.2010.01.021. Epub 2010 Jan 25.

Supplemental Content

Loading ...
Support Center